Latest News and Press Releases

OV101 in Angelman syndrome: Plan to meet with U.S. FDA in the fourth quarter of 2018 to review Phase 2 STARS results and discuss next steps for program OV935/TAK-935 in rare developmental and...

-- Additional data and analyses suggest that in the OV101 15 mg once-daily dose group, changes in sleep parameters and motor domains contributed to the statistically significant improvement in overall...

NEW YORK, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...

-- Alexander Kolevzon, M.D., to review additional data from company’s Phase 2 STARS trial with OV101 for the treatment of Angelman syndrome during the 65th American Academy of Child and Adolescent...

-- OV935 is being investigated for the treatment of pediatric patients with Dravet or Lennox-Gastaut syndromes in the ELEKTRA trial and pediatric patients with CDKL5 deficiency or Dup15q syndromes in...

NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...

Dr. Werber will join Cowen and Company as Managing Director and Senior Biotechnology Analyst effective September 24, 2018 Ovid has initiated a search to select a new CFO NEW YORK, Sept. 04, 2018 ...

NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...

-  Poster presentation of STARS topline data: the first clinical trial to show a positive clinical benefit on overall Angelman syndrome impairments  - NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) --...

-- OV101 in Angelman syndrome: plan to initiate an open-label extension study (ELARA) in the fourth quarter of 2018 and discuss with regulatory authorities next steps for a registrational pathway...